Accordingly, NPAS2 was included in a five-gene signature (DKK1, CCL20, NPAS2, GNPNAT1 and MELTF) predicting poor prognosis and decreased immunotherapy response in lung adenocarcinoma patients [101]. The gene discussed is NPAS2; the disease is lung adenocarcinoma.